A radiologist and public health expert breaks down what we know about President Trump's CT scan, and what this means for his ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians ...

About SHINE Technologies, LLC Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, ...

Holdings completed the previously announced sale of its single photon emission computed tomography business to SHINE Technologies.

In an interview with the Wall Street Journal published Thursday, President Trump revealed that he received a CT instead of an ...

The installation project also included a full renovation of the scanning room at Wellington Regional Hospital.

ART-101 is a novel small molecule for prostate cancer imaging and treatment, showing improved tumor uptake and reduced normal tissue uptake. The phase 1 trial will assess safety, biodistribution, and ...

Background: ATTR-CA is associated with heart failure (HF) and premature death. It is diagnosed non-invasively with radionuclide imaging, most commonly using 99mTc-pyrophosphate (PYP). Recent advances ...

With Lutetium-177 [177Lu]Lu-PSMA-617 radiopharmaceutical therapy being FDA-approved for metastatic castration-resistant prostate cancer (mCRPC) with an improvement in overall survival (OS), 1,2 there ...